AKTX akaritx.com: Multiplikator EV/Sales

Akari Therapeutics (AKTX) develops high-precision therapies for rare immune pathologies by targeting blood proteins. The EV/Sales multiple history demonstrates the market's reaction to these developments, where 0.00 shapes the current metric. However, the development of the orphan pipeline and asset integration require oversight, while global supply chain instability creates risks for international trials and patent protection.
Rincian metrik keuangan lan pasar Akari Therapeutics plc (AKTX)

This indicator reflects the ratio of total enterprise value to annual sales, allowing for an assessment of the market value of assets excluding debt load. By analyzing the current enterprise value-to-revenue multiple, an investor can determine the degree to which the asset is overbought, which is critically important for Akari Therapeutics (AKTX) given the diversification of its developments in innovative proteins for the therapy of orphan diseases.